Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01844765
Title Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

chronic myeloid leukemia

Therapies

Nilotinib

Age Groups: child
Covered Countries USA | ITA | FRA | ESP

Facility Status City State Zip Country Details
Loma Linda University Cancer Center Loma Linda California 92350 United States Details
Lucile Salter Packard Children's Hospital at Stanford Palo Alto California 94304 United States Details
Nemours Childrens Hospital Orlando Florida 32827 United States Details
St. Mary's Hospital West Palm Beach Florida 33407 United States Details
Johns Hopkins Oncology Center ORA Baltimore Maryland 21231 United States Details
UNC Chapel Hill Chapel Hill North Carolina 27599 United States Details
Nationwide Childrens Hospital Columbus Ohio 43205 United States Details
University of Texas Southwestern Medical Center Oncology Dallas Texas 75235 United States Details
Cook Children's Medical Center Oncology Fort Worth Texas 76104 United States Details
Seattle Childrens Hospital Seattle Washington 98105 United States Details
Novartis Investigative Site Bordeaux Aquitaine 33076 France Details
Novartis Investigative Site Lille 59000 France Details
Novartis Investigative Site Paris Cedex 75019 France Details
Novartis Investigative Site Poitiers 86021 France Details
Novartis Investigative Site Budapest 1094 Hungary Details
Novartis Investigative Site Genova GE 16147 Italy Details
Novartis Investigative Site Monza MB 20900 Italy Details
Novartis Investigative Site Padova PD 35128 Italy Details
Novartis Investigative Site Torino TO 10126 Italy Details
Novartis Investigative Site Yokohama-city Kanagawa 232-8555 Japan Details
Novartis Investigative Site Sakyo Ku Kyoto 606 8507 Japan Details
Novartis Investigative Site Shinjuku-ku Tokyo 160 8582 Japan Details
Novartis Investigative Site Saitama 330 8777 Japan Details
Novartis Investigative Site Shizuoka 420 8660 Japan Details
Novartis Investigative Site Seoul 03080 Korea, Republic of Details
Novartis Investigative Site Seoul 06351 Korea, Republic of Details
Novartis Investigative Site Kuala Lumpur 50589 Malaysia Details
Novartis Investigative Site Rotterdam 3015 CE Netherlands Details
Novartis Investigative Site Moscow 117198 Russian Federation Details
Novartis Investigative Site Madrid 28009 Spain Details
Novartis Investigative Site Muang Chiangmai 50200 Thailand Details
Novartis Investigative Site Bangkok 10330 Thailand Details
Novartis Investigative Site Bangkok 10700 Thailand Details
Novartis Investigative Site Istanbul 34093 Turkey Details
Novartis Investigative Site Sutton Surrey SM2 5PT United Kingdom Details
Novartis Investigative Site Bristol BS2 8BJ United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field